OncoMatch/Leukemia — Acute Myeloid (AML)/TP53
Leukemia — Acute Myeloid (AML)TP53 Clinical Trials
TP53 mutations occur in 5–10% of AML and are strongly associated with complex karyotype, therapy-related AML, and very poor prognosis with standard therapies. No agent is yet specifically approved for TP53-mutant AML, though eprenetapopt (APR-246) and decitabine/cedazuridine combinations have been studied. Trials evaluate novel p53-reactivating agents, hypomethylating regimens, and allogeneic transplant strategies for this high-risk population.
Top recruiting TP53 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count.
See all trials matched to your profile →Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
St. Petersburg State Pavlov Medical University
Oral-ATO for TP53-mutated Myeloid Malignancies
The University of Hong Kong